Following the release of the federal government's fiscal year 2014 omnibus appropriations legislation on Monday, medical device industry professionals lauded the government's decision to restore user fees that were lost in 2013 due to the sequester.
Members of Congress unveiled a massive bipartisan omnibus budget bill Monday that would partially repeal sharp spending cuts known as sequestration, restoring some funding to the National Institutes of Health.
The medical community welcomed a budget deal struck Tuesday night by the U.S. Congress, which, if approved, would restore funding to the National Institutes of Health, among other federal programs, that had been slashed under sequestration earlier this year.
NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.
Federal science funding hit a historic low in March with sequestration, and on top of several years of cuts, most scientists are spending more time writing federal grants today yet are receiving less grant funding now than they were just three years ago in 2010, according to a new survey.
Echoing their counterparts in the House, 5 senators from both parties have introduced a bill that would spare millions of FDA dollars from mandatory budget cuts, allowing the agency to use industry-provided money to speed up approvals.
A bipartisan congressional group has proposed a bill that would unlock millions in FDA user fees, industry-paid funds currently hamstrung by across-the-board sequester cuts.
The Senate Appropriations Committee approved a bill Wednesday that would provide $30.95 billion in funds for the National Institutes of Health for fiscal year 2014--an increase of $307 million from the agency's current budget.
The National Institutes of Health on Monday laid out the impact that sequestration--automatic, across-the-board reductions in federal spending that went into effect March 1--will have on biomedical research and the agency's overall operations.
Congressional budget battles are holding hostage millions of additional dollars the medical device industry agreed to pay in new FDA user fees to help fund an improved, more transparent regulatory process.